Spero Therapeutics Stock Analysis
SPRO Stock | USD 2.56 0.10 3.76% |
Spero Therapeutics is overvalued with Real Value of 1.71 and Target Price of 5.0. The main objective of Spero Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Spero Therapeutics is worth, separate from its market price. There are two main types of Spero Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Spero Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Spero Therapeutics is usually not traded on Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day. Spero Stock trading window is adjusted to America/New York timezone.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. Spero Stock Analysis Notes
About 24.0% of the company outstanding shares are owned by corporate insiders. The book value of Spero Therapeutics was at this time reported as 0.61. The company recorded a loss per share of 1.29. Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Spero Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. To find out more about Spero Therapeutics contact the company at (857) 242-1600 or learn more at https://sperotherapeutics.com.Spero Therapeutics Investment Alerts
Spero Therapeutics is way too risky over 90 days horizon | |
Spero Therapeutics appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 27.4 M. Net Loss for the year was (68.57 M) with loss before overhead, payroll, taxes, and interest of (48.45 M). | |
Spero Therapeutics currently holds about 45.4 M in cash with (23.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29. | |
Roughly 24.0% of the company outstanding shares are owned by corporate insiders | |
Latest headline from newsweek.com: Is California pushing for noncitizens to oversee elections What to know |
Spero Therapeutics Upcoming and Recent Events
Earnings reports are used by Spero Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
4th of April 2024 Upcoming Quarterly Report | View | |
9th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
4th of April 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Spero Largest EPS Surprises
Earnings surprises can significantly impact Spero Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2022-11-14 | 2022-09-30 | -0.3 | -0.33 | -0.03 | 10 | ||
2024-08-05 | 2024-06-30 | -0.38 | -0.33 | 0.05 | 13 | ||
2025-03-11 | 2024-12-31 | -0.31 | -0.3669 | -0.0569 | 18 |
Spero Therapeutics Environmental, Social, and Governance (ESG) Scores
Spero Therapeutics' ESG score is a quantitative measure that evaluates Spero Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Spero Therapeutics' operations that may have significant financial implications and affect Spero Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Spero Stock Institutional Investors
Shares | Citadel Advisors Llc | 2024-12-31 | 172.9 K | Bridgeway Capital Management, Llc | 2025-03-31 | 154.8 K | State Street Corp | 2025-03-31 | 148.9 K | Dafna Capital Management Llc | 2025-03-31 | 125 K | Squarepoint Ops Llc | 2025-03-31 | 92.9 K | Northern Trust Corp | 2024-12-31 | 86.4 K | Jpmorgan Chase & Co | 2025-03-31 | 60.8 K | Prudential Financial Inc | 2025-03-31 | 56 K | Jane Street Group Llc | 2024-12-31 | 52.9 K | Anson Funds Management Lp | 2025-03-31 | 3.8 M | Pfizer Inc | 2025-03-31 | 2.4 M |
Spero Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 148.72 M.Spero Profitablity
The company has Profit Margin (PM) of (1.56) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.48) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.48.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.62) | (0.65) | |
Return On Capital Employed | (1.19) | (1.25) | |
Return On Assets | (0.62) | (0.65) | |
Return On Equity | (1.49) | (1.56) |
Management Efficiency
Spero Therapeutics has return on total asset (ROA) of (0.3721) % which means that it has lost $0.3721 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0728) %, meaning that it created substantial loss on money invested by shareholders. Spero Therapeutics' management efficiency ratios could be used to measure how well Spero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 6th of June 2025, Return On Tangible Assets is likely to drop to -0.65. In addition to that, Return On Capital Employed is likely to drop to -1.25. At this time, Spero Therapeutics' Total Assets are very stable compared to the past year. As of the 6th of June 2025, Debt To Assets is likely to grow to 0.05, while Net Tangible Assets are likely to drop about 70.9 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.85 | 0.81 | |
Tangible Book Value Per Share | 0.85 | 0.81 | |
Enterprise Value Over EBITDA | (0.10) | (0.10) | |
Price Book Value Ratio | 1.21 | 1.15 | |
Enterprise Value Multiple | (0.10) | (0.10) | |
Price Fair Value | 1.21 | 1.15 | |
Enterprise Value | 7.1 M | 6.7 M |
The strategic initiatives led by Spero Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 6th of June, Spero Therapeutics has the Semi Deviation of 3.3, coefficient of variation of 806.99, and Risk Adjusted Performance of 0.2174. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Spero Therapeutics, as well as the relationship between them.Spero Therapeutics Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Spero Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Spero Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Spero Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spero Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spero Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spero Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spero Therapeutics Outstanding Bonds
Spero Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Spero Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Spero bonds can be classified according to their maturity, which is the date when Spero Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
MGM Resorts International Corp BondUS552953CD18 | View | |
Valero Energy Partners Corp BondUS91914JAA07 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Spero Therapeutics Predictive Daily Indicators
Spero Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Spero Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Spero Therapeutics Corporate Filings
8K | 28th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 13th of May 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 6th of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 28th of April 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
28th of March 2025 Other Reports | ViewVerify | |
10K | 27th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 28th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Spero Therapeutics Forecast Models
Spero Therapeutics' time-series forecasting models are one of many Spero Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Spero Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Spero Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Spero Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Spero shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Spero Therapeutics. By using and applying Spero Stock analysis, traders can create a robust methodology for identifying Spero entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (2.50) | (2.63) | |
Operating Profit Margin | (2.68) | (2.81) | |
Net Loss | (2.50) | (2.63) | |
Gross Profit Margin | 1.00 | 1.05 |
Current Spero Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Spero analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Spero analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
5.0 | Buy | 3 | Odds |
Most Spero analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Spero stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Spero Therapeutics, talking to its executives and customers, or listening to Spero conference calls.
Spero Stock Analysis Indicators
Spero Therapeutics stock analysis indicators help investors evaluate how Spero Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Spero Therapeutics shares will generate the highest return on investment. By understating and applying Spero Therapeutics stock analysis, traders can identify Spero Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 76.3 M | |
Common Stock Shares Outstanding | 54 M | |
Total Stockholder Equity | 46.1 M | |
Quarterly Earnings Growth Y O Y | 0.753 | |
Property Plant And Equipment Net | 3.1 M | |
Cash And Short Term Investments | 52.9 M | |
Cash | 52.9 M | |
Accounts Payable | 7.3 M | |
Net Debt | -48.6 M | |
50 Day M A | 0.8993 | |
Total Current Liabilities | 49.1 M | |
Other Operating Expenses | 100.8 M | |
Non Current Assets Total | 3.3 M | |
Non Currrent Assets Other | 153 K | |
Stock Based Compensation | 7.8 M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share (1.29) | Revenue Per Share | Quarterly Revenue Growth (0.37) | Return On Assets |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.